-
Barclays Capital Is Lowering Incyte Corporation (INCY) FY14 Estimate To 0.02 From 0.10
5/3/2013
|
-
Barclays Capital Is Cutting Incyte Corporation (INCY) FY13 Estimate To -0.09 From 0.07
5/3/2013
|
-
Incyte Corp. Q1 Loss Narrows To $15.7 Mln Or $0.12/shr From $45.4 Mln Or $0.36/shr Last Year
5/2/2013
|
-
Incyte Earns $25 Mln Milestone As C-MET Inhibitor INC280 Advances Into Phase II Development
4/29/2013
|
|
|
|
|
-
Barclays Capital Is Increasing Incyte Corporation (INCY) FY13 Estimate To 0.07 From -0.09
2/15/2013
|
|
|
-
Incyte Q4 EPS $0.14 Vs. Loss $0.44 Prior Year
2/14/2013
|
-
Barclays Capital Is Raising Incyte Corporation (INCY) FY12 Estimate To 0.11 From 0.10
1/24/2013
|